PD-L1 expression reflects pre-existing antitumor immunity in the TME and has been associated with a clinical benefit from anti-PD-1/PD-L1 blockade across multiple cancer types, including NSCLC [73–75]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.